Introduction {#s1}
============

Traditionally, patients with venous thromboembolism (VTE) are treated with low molecular weight heparins (LMWH) and vitamin K antagonists (VKA) such as warfarin, acenocoumarol or phenprocoumon [@pone.0042269-Hull1], [@pone.0042269-Hull2]. As with any medical treatment, the weighing of risks and benefits must be carefully balanced. The effect of VKA therapy depends on many factors including variation in dose response between patients, individual variation in pharmacokinetics and pharmacodynamic response, multiple interactions with food, co- medication and finally also by variation in adherence [@pone.0042269-Buller1], [@pone.0042269-Hirsh1]. VKA have a narrow therapeutic index, which needs to be monitored carefully in order to reduce the risk of tromboembolic events as well as bleeding complications [@pone.0042269-Hull3]. With the large scale clinical testing of novel, direct acting oral anticoagulants, including the thrombin and factor Xa inhibitors dabigatran and rivaroxaban, a new era has been heralded. The main advantage of these new anticoagulants is the lack of a need for laboratory monitoring and dose adjustment due to more stable pharmacokinetics [@pone.0042269-Eriksson1]. Several recent large randomized controlled trials have shown non-inferiority in effectiveness and safety of the new anticoagulants compared to VKA treatment [@pone.0042269-Bottic1], [@pone.0042269-Schulman1], [@pone.0042269-The1], [@pone.0042269-Connolly1], [@pone.0042269-ROCKETAFStudyInvestigators1]. However, the percentage of time within therapeutic range in the VKA-group, representing the quality of the control group, appears to vary considerably among these studies.

![Flow diagram of literature search.](pone.0042269.g001){#pone-0042269-g001}

The International Normalized Ratio (INR), the ratio of a patient\'s prothrombin time to a normal (control) sample, raised to the power of the International Sensitivity Index (ISI) value, is established by the World Health Organization (WHO) and the International Committee on Thrombosis and Hemostasis for monitoring the effects of VKA. A target INR range of 2.0 to 3.0 is recommended for the treatment of VTE [@pone.0042269-Buller1]. The most recognized way to measure the therapeutic effectiveness of VKA over time is to measure the percentage of time in the therapeutic range (TTR). TTR has been shown to strongly correlate with the clinical outcomes of hemorrhage or thrombosis and, thus, TTR is a reliable measure of the quality of anticoagulation management [@pone.0042269-Phillips1].

10.1371/journal.pone.0042269.t001

###### Study characteristics of included studies.
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                                            Study design/                   \% with   Included                                                         Definition               Method
  -------------------------------- -------------------------------- ------ --------- ---------- ---------------------------------------------------- --------------- -----------------------------
  Research Committee of                                              358     3.6%                       UFH and Warfarin (4 weeks treatment)                         
  British Thoracic Society, 1992           RCT/duration OAC          354     2.8%       VTE            UFH and Warfarin (3 months treatment)          INR 2.0--3.0          Classes of %TTR
  Agnelli, 2001                            RCT/duration OAC          267      0%        DVT               LMWH and Warfarin/Acenocoumarol             INR 2.0--3.0       Linear Interpolation
  Agnelli, 2003                            RCT/duration OAC          326      0%         PE               LMWH and Warfarin/Acenocoumarol             INR 2.0--3.0       Linear Interpolation
  Agnelli, 2007                            RCT/dose-finding          126     \<3%       DVT               LMWH and Warfarin/Acenocoumarol             INR 2.0--3.0                NR
                                                                     172      1%                 LMWH and VKA local practice (outpatient treatment)                  
  Aujeskey, 2011                    RCT/outpatients vs. inpatients   172      2%         PE      LMWH and VKA local practice (inpatient treatment)    INR 2.0--3.0       Linear Interpolation
  Van Bladel, 2010                      Cohort of PE patients         86      14%        PE                    LMWH and Acenocoumarol                 INR 2.0--3.5       Linear Interpolation
                                                                     104     100%                                                                                    
  Bona, 2000                        Cohort with and without cancer   208      0%        VTE                           Warfarin                        INR 2.0--3.0       Linear Interpolation
                                                                     1103    10.2%                      Fondaparinux and VKA local practice                          
  Büller, 2003                           RCT/medication trial        1110    11.5%       PE                  UFH and VKA local practice               INR 2.0--3.0       Linear Interpolation
                                                                                                            LMWH/UFH and Warfarin/Aceno-                             
  Büller, 2008                             RCT/dose-finding          137     7.3%       DVT               coumarol/Phenprocoum/Fluindione             INR 2.0--3.0       Linear Interpolation
  Caprini, 1999                     Cohort/INR and DVT resolution     33     22.7%      DVT                       UFH and Warfarin                    INR 2.0--3.0                NR
  Cassiopea Investigators, 2012          RCT/medication trial        1603     6%         PE                      LMWH and Warfarin                    INR 2.0--3.0       Linear Interpolation
                                                                     510     23.3%                          LMWH and coumarin derivative                             
  Columbus Invesigators, 1997            RCT/medication trial        511     22.1%      VTE                 UFH and coumarin derivative               INR 2.0--3.0                NR
  Das, 1996                              RCT/medication trial         55     5.5%       DVT                      LMWH and Warfarin                    INR 2.0--3.0                NR
  Daskapoulos, 2005                      RCT/medication trial         52     15.4%      DVT                    UFH and Acenocoumarol                  INR 2.0--3.0                NR
                                                                                                                                                                      after discontinuation LMWH
                                                                                                                                                                        until end of treatment,
  Einstein Investigators, 2010           RCT/medication trial        1718    5.2%       DVT               LMWH and Warfarin/Acenocoumarol             INR 2.0--3.0      including interruptions
                                                                                                                                                                      after discontinuation LMWH
                                                                                                                                                                        until end of treatment,
  Einstein Investigators, 2012           RCT/medication trial        2413    4.5%        PE               LMWH and Warfarin/Acenocoumarol             INR 2.0--3.0    corrected for interruptions
  Fiesinger, 2005                        RCT/medication trial        1249    13.5%      VTE                LMWH (Enoxaparin) and Warfarin             INR 2.0--3.0                NR
                                                                     360     22.2%                                UFH and Warfarin                                   
  Galilei Investigators, 2004            RCT/medication trial        360     21.1%      VTE                      LMWH and Warfarin                    INR 2.0--3.0          Classes of %TTR
                                                                     1452    9.5%       DVT                                                                          
  Van Gogh Investigators, 2007           RCT/medication trial        1120    8.4%        PE            LMWH/UFH and Warfarin/Acenonocoumarol          INR 2.0--3.0       Linear Interpolation
  Gonzalez-Fajardo, 1999                 RCT/medication trial         80      10%       DVT                       UFH and Coumarin                    INR 2.0--3.0       Linear Interpolation
  Heidinger, 2000                     Cohort/self-management OAC     622      NR        VTE               VKA according to local practice             INR 2.0--3.0          Last 12 values
  Kearon, 1999                             RCT/duration OAC          162      0%        VTE                    LMWH/UFH and Warfarin                  INR 2.0--3.0       Linear Interpolation
  Kearon, 2003                             RCT/dose-finding          369      0%        VTE                    LMWH/UFH and Warfarin                  INR 2.0--3.0       Linear Interpolation
  Kearon, 2004                           RCT/duration of OAC         165      0%        VTE                    LMWH/UFH and Warfarin                  INR 2.0--3.0       Linear Interpolation
                                                                     355     16.6%                                UFH and Warfarin                                   
  Kearon, 2006                           RCT/medication trial        353     15.0%      VTE                      LMWH and Warfarin                    INR 2.0--3.0       Linear Interpolation
                                                                     198     18.2%                           UFH and VKA local practice                              
  Koopman, 1996                          RCT/medication trial        202     16.8%      DVT                 LMWH and VKA local practice               INR 2.0--3.0       Linear Interpolation
  Levine, 1995                             RCT/duration OAC          109     21.1%      DVT                       UFH and Warfarin                    INR 2.0--3.0                NR
  López-Beret, 2001                      RCT/medication trial         77     23.3%      DVT             LMWH (Nadroparin) and Acenocoumarol           INR 2.0--3.0       Linear Interpolation
  Meyer, 2002                            RCT/medication trial         75     100%       VTE                      LMWH and Warfarin                    INR 2.0--3.0                NR
  Monreal, 1998                         Cohort of VTE patients       244     13.5%      VTE                LMWH (Dalteparin) and Coumarin             INR 2.0--3.0       Linear Interpolation
  Nielsen, 1993                          RCT/medication trial         46     8.7%       DVT                      UFH/Phenprocouman                    INR 2.0--3.0                NR
                                                                     733      0%                                                                                     
  Palareti, 2000                    Cohort with and without cancer    95     100%       VTE                    Warfarin/Acenocoumarol                 INR 2.0--3.0       Linear Interpolation
  Pérez-de-Llano, 2010                   RCT/medication trial         50      6%         PE             LMWH (Tinzaparin) and Acenocoumarol           INR 2.0--3.0                NR
  Pini, 1994                             RCT/medication trial         94     24.5%      DVT                     Heparin and Warfarin                  INR 2.0--3.0          Classes of %TTR
                                      RCT computer-assisted OAC      1560     NR                         VKA local practice (Manual dosage)                          
  Poller, 2008                         dosage vs medical staff       1649     NR        VTE        VKA local practice (Computer-assisted dosage)      INR 2.0--3.0       Linear Interpolation
  Poli, 2007                            Cohort of VTE patients       182      0%        VTE                    LMWH/UFH and Warfarin                  INR 2.0--3.0         Median % of time
                                                                      90     16.7%                  LMWH/UFH and VKA local practice (stockings)                      
  Prandoni, 2004                      RCT/intervention stockings      90     11.1%      DVT        LMWH/UFH and VKA local practice (no stockings)     INR 2.0--3.0          Classes of %TTR
  Santamaria, 2006                    Cohort/cost-effectiveness      116     17.2%      VTE                    Acenocoumarol/Warfarin                 INR 2.0--3.0                NR
                                                                                                                                                                            Classes of %TTR
  Schulman, 1994                         RCT/duration of OAC         1124     0%        VTE                    LMWH/UFH and Warfarin                  INR 2.0--2.85      Linear Interpolation
  Schulman, 2009                         RCT/medication trial        1265    4.5%       VTE                    LMWH/UFH and Warfarin                  INR 2.0--3.0                NR

**Abbreviations:** RCT, Randomized Controlled Trial; OAC, oral anticoagulation; UFH, Unfractionated Heparin; LMWH, Low Molecular Weight Heparin; VTE, Venous ThromboEmbolism; DVT, Deep Vein Thrombosis; PE, Pulmonary Embolism; TR, Therapeutic Range; INR, International Normalized Ratio; NR, not reported.

Dabigatran and rivaroxaban have been recently approved in many countries including the USA, Canada and also in Europe. This development will cause major changes in thrombosis management in the near future. Cost-effectiveness studies and real life registries will be the next step in the implementation of new oral anticoagulants. In order to adequately compare all treatment options, including novel anticoagulants and VKA, and to interpret the relative efficacy and safety of these novel anticoagulants, it is important to properly assess the quality of anticoagulant control, i.e. TTR, in the VKA group. This systematic review tries to provide a benchmark of TTR in patients with VTE receiving VKA and discusses the pros and cons of various ways to calculate TTR. Finally, it emphasizes the need to standardize TTR reporting, thereby contributing to a meaningful comparison among treatment options in studies evaluating novel anticoagulants.

10.1371/journal.pone.0042269.t002

###### Quality assessment of the included studies.
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                                            Reasons for   Incomplete data   Efforts to address                     
  ------------------------------ --------- ------------- ----------------- -------------------- ------------------ ---------
  Research committee of                                                                                            
  British Thoracic                  Yes         Yes             Yes                Yes              12 months         8%
  Society, 1992                                                                                                    
  Agnelli, 2001                     Yes         Yes             Yes                Yes           at least 2 years     0%
  Agnelli, 2003                     Yes         Yes             Yes                Yes           at least 1 year      0%
  Agnelli, 2007                     Yes         Yes             Yes                Yes              at least 4        0%
                                                                                                      months       
  Aujeskey, 2011                    Yes         Yes             Yes                Yes               3 months        0.2%
  Van Bladel, 2010                  Yes         Yes             Yes                Yes               3 months        1.2%
  Bona, 2000                        Yes         No            Unclear            Unclear             Unclear        Unclear
  Büller, 2003                      Yes         Yes             Yes                Yes               3 months        0.5%
  Büller, 2008                    Unclear       No              Yes                Yes               3 months        0.7%
  Caprini, 1999                     Yes         Yes             No                  No               6 months       Unclear
  Cassiopea, 2012                   Yes         Yes             Yes                Yes             6--12 months     Unclear
  Columbus Investigators, 1997      Yes         Yes             Yes                Yes               3 months         0%
  Das, 1996                         Yes         Yes             Yes                Yes               3 months       Unclear
  Daskapoulos, 2005                 Yes         Yes             Yes                Yes              12 months         0%
  Einstein Investigators, 2010      Yes         Yes             Yes                Yes             3--12 months       1%
  Einstein Investigators, 2012      Yes         Yes             Yes              Unclear             Unclear         0.4%
  Fiesinger, 2005                 Unclear       Yes             Yes                Yes              6 ½ months       1.1%
  Galilei Investigators, 2004       Yes         Yes             Yes                Yes               3 months         0%
  Van Gogh Investigators, 2007      Yes         Yes             Yes                Yes               3 months        0.8%
  Gonzalez-Fajardo, 1999            Yes         Yes             Yes                Yes              12 months        1.6%
  Heidinger, 2000                   No          Yes             No               Unclear             Unclear        Unclear
  Kearon, 1999                      Yes         Yes             Yes                Yes              Average 10      Unclear
                                                                                                      months       
  Kearon, 2003                      Yes         Yes             Yes                Yes             Average 2.4       0.1%
                                                                                                      years        
  Kearon, 2004                      Yes         Yes             Yes                Yes              12 months         0%
  Kearon, 2006                      Yes         Yes             Yes                Yes               3 months         0%
  Koopman, 1996                     Yes         Yes             Yes                Yes               6 months         1%
  Levine, 1995                    Unclear       Yes             No                 Yes              12 months        3.4%
  López-Beret, 2001                 Yes         Yes           Unclear            Unclear            12 months       Unclear
  Meyer, 2002                       Yes         Yes           Unclear            Unclear             6 months       Unclear
  Monreal, 1998                     Yes         Yes           Unclear               No             3--6 months      Unclear
  Nielsen, 1993                     Yes         No            Unclear              Yes               3 months       Unclear
  Palareti, 2000                    Yes         Yes             Yes                Yes            Average 10--11    Unclear
                                                                                                      months       
  Pérez-de-Llano, 2010              Yes         Yes             Yes                Yes               6 months         6%
  Pini, 1994                        Yes         Yes             Yes                Yes               9 months         0%
  Poller, 2008                    Unclear       Yes           Unclear              Yes              Average 17      Unclear
                                                                                                      months       
  Poli, 2007                        Yes         Yes             Yes                Yes           At least 1 year     8.1%
                                                                                                     or until      
                                                                                                    recurrence     
  Prandoni, 2004                    Yes         Yes             Yes                Yes               5 years         1.7%
  Santamaria, 2006                Unclear       Yes             No                  No                Median        Unclear
                                                                                                     98 days       
  Schulman, 1994                  Unclear       Yes             Yes                Yes              At least 6      Unclear
                                                                                                      months       
  Schulman, 2009                  Unclear       Yes             Yes                Yes               6 months        0.5%

Materials and Methods {#s2}
=====================

Data sources and searches {#s2a}
-------------------------

A systematic search was performed to identify randomized controlled trials and cohort studies reporting the TTR in patients treated with VKA for deep vein thrombosis (DVT) confirmed by a non-compressible venous segment on an ultrasound of the extremities, or pulmonary embolism (PE) confirmed by an arterial filling defect on Computed Tomographic Pulmonary Angiography (CTPA) or a high probability ventilation/perfusion (V/Q) scan, or both (VTE). We searched Medline and Embase for articles in English, French, German, Dutch, Polish, Swedish, Danish, Italian and Spanish. Since the World Health Organization introduced the INR in 1983 [@pone.0042269-1] and the first studies reporting TTR in VKA in patients with VTE were published in the nineties, we searched for publications between January 1990 and May 2012. See Appendix 1 for detailed information about the search strategy and key words.

![Time in Therapeutic Range in individual studies.\
\* A weighted mean is calculated if a study reported more than 1 group; studies that only presented classes of %TTR are not represented here.](pone.0042269.g002){#pone-0042269-g002}

Study selection {#s2b}
---------------

To be eligible for inclusion, studies had to fulfill the following criteria:

1.  Study population consisted of consecutive adult patients with objectively confirmed DVT or PE.

2.  Patients were treated with VKA for a minimum of three months.

Studies were excluded if they only reported the TTR in the initial treatment period while patients were still on parental medication such as low molecular weight heparin and unfractionated heparin.

10.1371/journal.pone.0042269.t003

###### Percentage of time below, within and above the Therapeutic Range of the individual studies.
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                                                   Time-Period TTR                       TTR         
  ------------------------------------ ------ -------------------------- ------- ------------------- -------
  Research Committee of                 358            Month 1             NR     37.4% (\>67% TTR)    NR
  The British Thoracic Society, 1992    354         Months 1 to 3          NR     35.2% (\>67% TTR)    NR
  Agnelli, 2001                         267        Months 4 to 12+         NR            81%           NR
  Agnelli, 2003                         326        Months 4 to 12+         NR            83%           NR
  Agnelli, 2007                         126         Months 1 to 3          NR            60%           NR
  Aujeskey, 2011                        172                               34.7%         51.8%         13.5%
                                        172         Months 1 to 3          32%          52.5%         15.6%
  Van Bladel                             86         Months 1 to 3         12.1%          76%          11.8%
                                        104                                NR           47.5%          NR
  Bona, 2000                            208         Months 1 to 6+         NR            56%           NR
                                        1103                               28%           53%           19%
  Büller, 2003                          1110        Months 1 to 3          28%           52%           20%
  Büller, 2008                          137         Months 1 to 3          29%          50.3%         20.7%
                                                      At 1 month          42.4%         48.5%         12.1%
                                                     At 3 monhts          63.6%         39.4%          3%
  Caprini, 1999                          33          At 6 months          48.5%         45.5%         9.1%
  Cassiopea Investigators, 2012         1603        Months 1 to 6+        25.6%         55.9%         18.5%
                                        510                                22%           57%           21%
  The Columbus Invesigators, 1997       511         Months 1 to 3          24%           57%           21%
  Das, 1996                              55         Months 1 to 3          NR           68.8%          NR
  Daskapoulos, 2005                      52         Months 1 to 6+        19.1%         67.2%         13.6%
                                                       Month 1             NR           54.1%          NR
  The Einstein Investigators, 2010      1718        Months 1 to 6+        24.4%         57.7%         16.2%
  The Einstein Investigators, 2012      2413        Months 1 to 6+        21.8%         62.7%         15.5%
  Fiesinger, 2005                       1249        Months 1 to 6+         NR            61%           NR
                                        360                                NR     72.7% (≥70% TTR)     NR
  The Galilei Investigators, 2004       360         Months 1 to 3          NR      70% (≥70% TTR)      NR
                                        1452                              26.2%         54.4%         19.4%
  The van Gogh Investigators, 2007      1120        Months 1 to 6+        26.9%         54.8%         18.3%
  Gonzalez-Fajardo, 1999                 80         Months 1 to 3          15%           64%           21%
  Heidinger, 2000                       622    on average at 4.5 months   22.7%         69.2%         8.1%
  Kearon, 1999                          162        Months 4 to 12+         22%           64%           14%
  Kearon, 2003                          369        Months 4 to 12+         20%           69%           11%
  Kearon, 2004                          165         Months 2 to 3          29%           63%           8%
                                        355                                28%           55%           17%
  Kearon, 2006                          353         Months 1 to 3          25%           56%           19%
                                        198                                18%           56%           26%
  Koopman, 1996                         202         Months 1 to 3          16%           62%           22%
  Levine, 1995                          109         Months 2 to 3         29.6%         60.7%         9.7%
  López-Beret, 2001                      77         Months 1 to 6+        22.8%         67.8%         9.4%
  Meyer, 2002                            75         Months 1 to 3          NR            41%           NR
  Monreal, 1998                         244         Months 1 to 6+        25.5%         56.9%         17.6%
  Nielsen, 1993                          46         Months 1 to 3          NR            70%           NR
                                        733                               22.5%         63.6%         13.9%
  Palareti, 2000                         95         Months 1 to 6+        23.3%         58.9%         17.8%
  Pérez-de-Llano, 2010                   50         Months 1 to 6+        41.5%         51.7%         6.8%
  Pini, 1994                             94         Months 1 to 3+         NR      38% (≥67% TTR)      NR
                                        1560                               NR           64.9%          NR
  Poller, 2008                          1649        Months 1 to 6+         NR            66%           NR
  Poli, 2007                            182         Months 1 to 3         18.8%         69.7%         11.5%
                                         90                                NR      70% (\>70% TTR)     NR
  Prandoni, 2004                         90         Months 1 to 3+         NR     72.2% (\>70% TTR)    NR
  Santamaria, 2006                      116          At 3 months           NR           61.1%          NR
                                                     At 12 months          NR      63% (≥75% TTR)      NR
  Schulman, 1994                        1124        Months 1 to 6+         25%           58%           17%
  Schulman, 2009                        1265        Months 1 to 6+         21%           60%           19%

**Abbreviations:** TTR, Time in Therapeutic Range; TR, Therpeutic Range; INR, International Normalized Ratio; NR, Not Reported.

Data extraction and management {#s2c}
------------------------------

Three reviewers (PE, HTC, MP) operating in pairs of two extracted independently the following characteristics from each included study: study design, type of study (e.g. evaluation of a new drug, dose-finding, evaluation of duration of anticoagulation), characteristics of the study population (e.g. number of patients treated with VKA, country, inclusion criteria, proportion of patients with a malignancy), initial treatment, type of VKA (e.g. warfarin, acenocoumarol, phenprocoumon or other), initial dose of VKA, treatment duration, INR-monitoring by thrombosis service or self-management, percentage of time below therapeutic range (INR \<2), percentage of time within therapeutic range (INR 2.0--3.0), percentage of time above therapeutic range (INR \>3), method of calculation TTR and adverse events (e.g. recurrent VTE, major bleeding and mortality). The quality of the included studies was assessed by addressing the following issues: a) were consecutive patients included in the study?, b) did the authors report reasons for exclusion?, c) were incomplete data adequately addressed?, d) did the authors address potential sources of bias?, e) what was the duration of follow-up?, f) how many patients (percentage) were lost to follow-up?. Discrepancies were resolved by discussion. If agreement could not be reached a third reviewer was consulted.

10.1371/journal.pone.0042269.t004

###### Weighted mean % of time below, within and above Therapeutic Range INR 2.0--3.0.

![](pone.0042269.t004){#pone-0042269-t004-4}

  Time-period TTR                                             
  ------------------------------------------- ------- ------- -------
  **Month 1**                                                 
  (*n* studies = 2, *n* patients  = 1751)      42.4%   54.0%   12.1%
  **Months 1 to 3**                                           
  (*n* studies = 13, *n* patients  = 5473)     35.0%   55.6%   19.2%
  **Months 2 to 3**                                           
  (*n* studies = 4, *n* patients  = 423)       32.9%   60.0%   8.1%
  **Months 1 to 6+**                                          
  (*n* studies = 13, *n* patients  = 17338)    24.1%   60.0%   16.7%
  **Months 4 to 12+**                                         
  (*n* studies = 4, *n* patients  = 1124)      20.6%   75.2%   11.9%

**Abbreviations:** TTR, Time in Therapeutic Range; INR, International Normalized Ratio; TR, Therapeutic Range.

Data synthesis and analysis {#s2d}
---------------------------

A meta-analysis was performed by calculating a weighted mean, based on the number of participants in each included study, for each time-period in which the TTR was measured since the confirmation of the diagnosis of VTE.

![Suggestions for calculating TTR.\
Dark grey  =  reporting an overall TTR during treatment. Light grey  =  reporting the frequency of events as a function of TTR.](pone.0042269.g003){#pone-0042269-g003}

Results {#s3}
=======

Results of the search {#s3a}
---------------------

The systematic search yielded 3636 citations. The results were screened and after reading titles and abstracts 3154 articles were excluded. Of the remaining 482 publications the full text was assessed. ([Figure 1](#pone-0042269-g001){ref-type="fig"}).

Included studies {#s3b}
----------------

In total, 40 studies [@pone.0042269-Schulman1], [@pone.0042269-The1], [@pone.0042269-Agnelli1], [@pone.0042269-Agnelli2], [@pone.0042269-Agnelli3], [@pone.0042269-Bona1], [@pone.0042269-Buller2], [@pone.0042269-Buller3], [@pone.0042269-Caprini1], [@pone.0042269-Das1], [@pone.0042269-Daskalopoulos1], [@pone.0042269-Fiessinger1], [@pone.0042269-Gali1], [@pone.0042269-GonzalezFajardo1], [@pone.0042269-Heidinger1], [@pone.0042269-Kearon1], [@pone.0042269-Kearon2], [@pone.0042269-Kearon3], [@pone.0042269-Kearon4], [@pone.0042269-Koopman1], [@pone.0042269-Levine1], [@pone.0042269-LopezBeret1], [@pone.0042269-Meyer1], [@pone.0042269-Monreal1], [@pone.0042269-Nielsen1], [@pone.0042269-Palareti1], [@pone.0042269-PerezDeLlano1], [@pone.0042269-Pini1], [@pone.0042269-Poli1], [@pone.0042269-Poller1], [@pone.0042269-Prandoni1], [@pone.0042269-ResearchCommitteeoftheBritishThoracicSociety1], [@pone.0042269-Santamaria1], [@pone.0042269-Schulman2], [@pone.0042269-TheColumbusInvestigators1], [@pone.0042269-Theva1], [@pone.0042269-Aujesky1], [@pone.0042269-vanBladel1], [@pone.0042269-Cass1], [@pone.0042269-The2] reporting the TTR in 26064 patients treated with VKA for VTE were included in the analyses.

Most studies included patients with DVT as well as PE. Fifteen studies [@pone.0042269-The1], [@pone.0042269-Agnelli1], [@pone.0042269-Agnelli3], [@pone.0042269-Buller3], [@pone.0042269-Caprini1], [@pone.0042269-Das1], [@pone.0042269-Daskalopoulos1], [@pone.0042269-GonzalezFajardo1], [@pone.0042269-Koopman1], [@pone.0042269-Levine1], [@pone.0042269-LopezBeret1], [@pone.0042269-Nielsen1], [@pone.0042269-Pini1], [@pone.0042269-Prandoni1], [@pone.0042269-Theva1] reported the results from patients with only DVT and eight studies [@pone.0042269-Agnelli2], [@pone.0042269-Buller2], [@pone.0042269-PerezDeLlano1], [@pone.0042269-Theva1], [@pone.0042269-Aujesky1], [@pone.0042269-vanBladel1], [@pone.0042269-Cass1], [@pone.0042269-The2] reported the results from patients with only PE. The percentage of cancer ranged from 0% to 100%. The study characteristics of the included studies are presented in [Table 1](#pone-0042269-t001){ref-type="table"}. The quality assessment of each study is shown in [Table 2](#pone-0042269-t002){ref-type="table"}.

Methods of calculating TTR {#s3c}
--------------------------

Five studies [@pone.0042269-Gali1], [@pone.0042269-Pini1], [@pone.0042269-Prandoni1], [@pone.0042269-ResearchCommitteeoftheBritishThoracicSociety1], [@pone.0042269-Schulman2] reported TTR in classes ranging from \<33% to ≥75% of time spent within INR-range 2.0 to 3.0. (e.g. 57% of all patients spent 70% of time within therapeutic range). All other TTRs were reported in percentages over time. Two studies [@pone.0042269-The1], [@pone.0042269-Caprini1] reported the TTR in the first month since the start of treatment, thirteen studies [@pone.0042269-Agnelli1], [@pone.0042269-Buller2], [@pone.0042269-Buller3], [@pone.0042269-Das1], [@pone.0042269-GonzalezFajardo1], [@pone.0042269-Kearon3], [@pone.0042269-Koopman1], [@pone.0042269-Meyer1], [@pone.0042269-Nielsen1], [@pone.0042269-Poli1], [@pone.0042269-TheColumbusInvestigators1], [@pone.0042269-Aujesky1], [@pone.0042269-vanBladel1] reported the TTR measured in months 1 to 3, four studies [@pone.0042269-Caprini1], [@pone.0042269-Kearon2], [@pone.0042269-Levine1], [@pone.0042269-Santamaria1] measured the TTR in months 2 to 3, fifteen studies [@pone.0042269-Schulman1], [@pone.0042269-The1], [@pone.0042269-Bona1], [@pone.0042269-Daskalopoulos1], [@pone.0042269-Fiessinger1], [@pone.0042269-Heidinger1], [@pone.0042269-LopezBeret1], [@pone.0042269-Monreal1], [@pone.0042269-Palareti1], [@pone.0042269-PerezDeLlano1], [@pone.0042269-Poller1], [@pone.0042269-Schulman2], [@pone.0042269-Theva1], [@pone.0042269-Cass1], [@pone.0042269-The2] in months 1 to a minimum of 6 months and four studies [@pone.0042269-Agnelli2], [@pone.0042269-Agnelli3], [@pone.0042269-Kearon1], [@pone.0042269-Kearon4] reported the TTR in months 4 to at least 12 months since the start of treatment. Twenty (50%) studies [@pone.0042269-Agnelli2], [@pone.0042269-Agnelli3], [@pone.0042269-Bona1], [@pone.0042269-Buller2], [@pone.0042269-Buller3], [@pone.0042269-GonzalezFajardo1], [@pone.0042269-Kearon1], [@pone.0042269-Kearon2], [@pone.0042269-Kearon3], [@pone.0042269-Kearon4], [@pone.0042269-Koopman1], [@pone.0042269-LopezBeret1], [@pone.0042269-Monreal1], [@pone.0042269-Palareti1], [@pone.0042269-Poller1], [@pone.0042269-Schulman2], [@pone.0042269-Theva1], [@pone.0042269-Aujesky1], [@pone.0042269-vanBladel1], [@pone.0042269-Cass1] reported that they calculated the TTR by using linear interpolation [@pone.0042269-Rosendaal1]. The method used for calculating TTR was not mentioned in 12 (30.0%) studies [@pone.0042269-Schulman1], [@pone.0042269-Agnelli1], [@pone.0042269-Caprini1], [@pone.0042269-Das1], [@pone.0042269-Daskalopoulos1], [@pone.0042269-Fiessinger1], [@pone.0042269-Levine1], [@pone.0042269-Meyer1], [@pone.0042269-Nielsen1], [@pone.0042269-PerezDeLlano1], [@pone.0042269-Santamaria1], [@pone.0042269-TheColumbusInvestigators1] ([Table 1](#pone-0042269-t001){ref-type="table"}).

Percentage of time in therapeutic range {#s3d}
---------------------------------------

[Table 3](#pone-0042269-t003){ref-type="table"} presents the percentage of time below, within and above the therapeutic INR range of 2.0 to 3.0 of the individual studies. A histogram with the TTR in each individual study is given in [Figure 2](#pone-0042269-g002){ref-type="fig"}.

[Table 4](#pone-0042269-t004){ref-type="table"} details the weighted means for different time-periods since objective confirmation of the diagnosis VTE. The reported quality of VKA treatment is highly dependent on the time-period. In the first month the reported TTR is 54.0%. The TTR is 55.6% during the months 1 to 3 and 60.0% during a treatment of at least 6 months including the INRs in the first month. In studies reporting TTR without INRs in the first month, the TTR was 60.0% in months 2 to 3 since the start of treatment and 75.2% in the months 4 to 12 or longer.

Discussion {#s4}
==========

A strong relationship between TTR and bleeding or thromboembolic rates has been observed across a large number of studies with different patient populations [@pone.0042269-Ansell1]. Since under-anticoagulation gives inadequate protection against thromboembolic events and over-anticoagulation increases the bleeding risk, it is important to report the quality of VKA treatment by using the TTR [@pone.0042269-Hutten1]. The evidence for non-inferiority of new anticoagulants depends on the quality of the VKA control group. The present review provides a benchmark of TTR in patients with VTE receiving VKA and discusses the pros and cons of various ways to calculate TTR.

We included 40 studies with more than 26000 participants and the results indicate that the achieved TTR ranges from approximately 56% to 75%.

The reported quality of VKA treatment was highly dependent on the time-period since the start of treatment. A statistically significant lower TTR was seen in studies reporting a TTR that covers all INRs, including the first month, compared to studies reporting the TTR without the first month. This difference is to be expected because of the difficulty to reach the therapeutic range in the initial treatment period and improvement in TTR during continuation of VKA treatment. Another explanation of the high TTR during longterm treatments is a selection-to-continue bias. Patients with stable INRs are more likely to continue their treatment with VKA than patients who experience problems in reaching the therapeutic range [@pone.0042269-Kearon5]. However, even after 4 to 12 months of treatment with VKA, patients spent 25% of their time outside of the therapeutic range.

Our review has some limitations that have to be mentioned. First, methods used to calculate TTR differed across the included studies. Fifty percent of the studies used linear interpolation, a few studies reported the percentage of time in a certain TTR class and 30% of the studies did not report the method of TTR calculation at all. Due to missing information about the exact calculation of TTR, we were unable to compare the different methods in a meaningful way. In literature, several methods to assess therapeutic control are described: e.g. the assessment of the number of INR measurements within the target range expressed as a percentage of the total number of INRs obtained, the cross-section-of the-files technique (the fraction of patients in range at one point in time compared to the total number of patients who had an INR at that point in time), equidivision, linear interpolation and the hybrid method [@pone.0042269-Rosendaal1], [@pone.0042269-Duxbury1], [@pone.0042269-Loeliger1]. Each approach has its advantages and disadvantages. A disadvantage of the first two methods is that they do not incorporate time and therefore cannot be used to calculate incidence rates of recurrences at different INR levels [@pone.0042269-Hutten1]. Time is incorporated in the method of equidivision, which assumes that the change between two consecutive INR measurements occurred halfway the interval [@pone.0042269-Duxbury1]. The time spent in INR ranges can also be estimated by linear interpolation, which assumes that the INR between two measurements varies linearly from the first INR to the second INR [@pone.0042269-Rosendaal1]. A disadvantage of these last two methods is that extreme out of range INR values may bias overall results [@pone.0042269-Veeger1]. The hybrid method, in addition, takes effects of dosage modifications into account [@pone.0042269-Hutten1]. The results of all of these methods depend on whether an exact (INR 2.0--3.0) or an expanded therapeutic range is used, whether VKA-naïve patients (those just beginning therapy) are included or only patients already on established therapy, whether INRs obtained during invasive procedures when VKA therapy might be interrupted are excluded, and whether different oral anticoagulant preparations (e.g. warfarin or acenocoumarol) are allowed [@pone.0042269-Ansell1]. In a comparison of the equidivision, linear interpolation and hybrid methods, linear interpolation has been suggested as the preferred method as it shows a high validity and reproducibility [@pone.0042269-Hutten1]. We suggest that drug trials and real life registries with a VKA control group report the TTR in a uniform manner, to allow adequate comparison of data. Since linear interpolation has a high validity and was the most common method used to calculate TTR in the present review, we recommend to use linear interpolation in future studies covering the INRs from each patient from the discontinuation of heparin until the end of treatment. In order to avoid complex calculations, we believe that including time-periods with interruptions in VKA treatment in the TTR are acceptable. However, for calculating the relationship between TTR and adverse events, such as major bleeding episodes and thromboembolic events, we would suggest to exclude bridging periods, since the TTR will not represent the quality of anticoagulant treatment during these periods when most patients receive LMWH ([Figure 3](#pone-0042269-g003){ref-type="fig"}).

A second important limitation of the present review is that we were not able to investigate the association between TTR and clinical endpoints. Several studies in literature show a strong relationship between TTR and bleeding or thromboembolic events [@pone.0042269-Ansell1]. Unfortunately, data on such clinical endpoints related to TTR was not provided in the included studies.

Additionally, some other interesting sub-analyses were difficult due to small subgroups and the absence of detailed data. Hutten et al. indicated that the therapeutic quality of treatment was decreased when patients were treated with acenocoumarol rather than with warfarin [@pone.0042269-Hutten2]. This might implicate that the use of warfarin is preferable. However, since it is not clear whether these results might be influenced by factors such as frequency of monitoring and comorbidities, we need to be careful with drawing a conclusion. Furthermore, Hutten et al. showed that TTR was decreased in the presence of cancer and in the presence of a pulmonary embolism [@pone.0042269-Hutten2]. The same subgroup analyses in the present review did not show statistically significant results (data not shown). This might be explained by the fact that we did not have individual patient data (IPD). An IPD meta-analysis may give more detailed information for investigating such associations and may be interesting. Hutten et al. also showed a decrease in the therapeutic quality of VKA treatment when more than four changes in co-medication occurred [@pone.0042269-Hutten2]. Unfortunately such data was not available for our review.

The main conclusion of our systematic review is that the reported quality of VKA treatment is highly dependent on the time-period since the start of treatment, with the TTR ranging from approximately 56% in studies including the first month to 75% in studies excluding the first 3 months. The clinical consequences of our findings are not straightforward. However, it needs to be emphasized that the reported quality of VKA treatment should be taken into consideration while interpreting results from trials with new anticoagulants. Assuming an average treatment duration of 6 months, the mean TTR is approximately 60%. We recommend to calculate the TTR by using linear interpolation covering the INRs from each patient from discontinuation of heparin until the end of treatment. Furthermore, TTR is predictive of thromboembolic and bleeding complications for patients on VKA [@pone.0042269-Ansell1]; therefore a proper calculation of TTR in the VKA group is of importance in assessing the adequacy and quality of novel anticoagulants.

Oral anticoagulants are also effective in preventing stroke [@pone.0042269-2], [@pone.0042269-EAFTEuropeanAtrialFibrillationTrialStudyGroup1], [@pone.0042269-Ezekowitz1], [@pone.0042269-Petersen1], [@pone.0042269-The3] and prolonging survival rates in patients with atrial fibrillation (AF) [@pone.0042269-Currie1]. It may be interesting to investigate a benchmark of the TTR in patients treated with VKA in AF in the near future. However, since patients with AF are usually on long-term VKA treatment, selection-to-continue bias will be more evident than in patients with VTE and should be taken into consideration in an analysis in AF patients [@pone.0042269-Kearon5].
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